BRPI0412000A - tratamento de cáncer com epotilonas - Google Patents

tratamento de cáncer com epotilonas

Info

Publication number
BRPI0412000A
BRPI0412000A BRPI0412000-0A BRPI0412000A BRPI0412000A BR PI0412000 A BRPI0412000 A BR PI0412000A BR PI0412000 A BRPI0412000 A BR PI0412000A BR PI0412000 A BRPI0412000 A BR PI0412000A
Authority
BR
Brazil
Prior art keywords
epothilone
cancer treatment
treatment
administration
epotilones
Prior art date
Application number
BRPI0412000-0A
Other languages
English (en)
Inventor
David Parkinson
Ivo Sklenar
Sara Zaknoen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0412000A publication Critical patent/BRPI0412000A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

"TRATAMENTO DE CáNCER COM EPOTILONAS". A presente invenção refere-se ao emprego de uma epotilona para o tratamento de uma doença proliferativa que compreende a etapa de administração diária de uma quantidade terapeuticamente eficaz de uma epotilona através de administração intravenosa (i.v.) contínua.
BRPI0412000-0A 2003-06-27 2004-06-25 tratamento de cáncer com epotilonas BRPI0412000A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48326303P 2003-06-27 2003-06-27
PCT/EP2004/006921 WO2005000292A1 (en) 2003-06-27 2004-06-25 Cancer treatment with epothilones

Publications (1)

Publication Number Publication Date
BRPI0412000A true BRPI0412000A (pt) 2006-08-15

Family

ID=33552048

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412000-0A BRPI0412000A (pt) 2003-06-27 2004-06-25 tratamento de cáncer com epotilonas

Country Status (9)

Country Link
US (1) US20060205795A1 (pt)
EP (1) EP1641449A1 (pt)
JP (1) JP2009513486A (pt)
CN (1) CN1812780A (pt)
AU (1) AU2004251444B2 (pt)
BR (1) BRPI0412000A (pt)
CA (1) CA2530311A1 (pt)
MX (1) MXPA05013958A (pt)
WO (1) WO2005000292A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1870995A (zh) * 2003-09-02 2006-11-29 诺瓦提斯公司 使用埃坡霉素的癌症治疗
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
AU2003279911A1 (en) * 2002-10-09 2004-05-04 Kosan Biosciences, Inc. Therapeutic formulations

Also Published As

Publication number Publication date
AU2004251444A1 (en) 2005-01-06
EP1641449A1 (en) 2006-04-05
US20060205795A1 (en) 2006-09-14
CA2530311A1 (en) 2005-01-06
WO2005000292A1 (en) 2005-01-06
JP2009513486A (ja) 2009-04-02
CN1812780A (zh) 2006-08-02
AU2004251444B2 (en) 2008-05-22
MXPA05013958A (es) 2006-02-24

Similar Documents

Publication Publication Date Title
AR025444A1 (es) Derivados de sulfonil-carboxamida, procedimientos para su preparacion y su utilizacion como medicamentos
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
IL175762A0 (en) Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease
BR0315630A (pt) Administração de combinação de uma indolinona com um agente quimioterapêutico para distúrbios de proliferação celular
BR0312729A (pt) Novos derivados de indol-3-enxofre
CY1111433T1 (el) Φαρμακευτικο τυποποιημενο παρασκευασμα δεσιταβινης
MX2009002920A (es) Tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos.
GT200200188A (es) Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
BR0308154A (pt) Emprego de epotilonas no tratamento de doenças cerebrais associadas com processos proliferativos
BRPI0520258A2 (pt) uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina
BRPI0508232A (pt) sìntese de epotilonas, intermediários das mesmas, análogos e usos das mesmas
BRPI0511305A (pt) método de aliviar um granuloma anular ou sarcóide, artigo manufaturado e uso de um antagonista de lfa-1
BRPI0414043A (pt) tratamento de cáncer com epotilonas
BRPI0412000A (pt) tratamento de cáncer com epotilonas
IS8059A (is) Meðhöndlun fjölgunarsjúkdóma með epóþílónafleiðumog geislun
TW200501946A (en) Pharmaceutical composition for the treatment of schizophrenia in a patient with overweight
CR8584A (es) Piperazinas derivadas de urea para el tratamiento de la endometrosis
DK1675611T3 (da) Terapeutiske anvendelser for C-peptid
SE0004827D0 (sv) Therapeutic compounds
BRPI0407781A (pt) aplicação combinada de ribavirina e interferon beta em doenças desmielinizantes
BR0213633A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ou ativação aberrante de leucócitos
BRPI0415428A (pt) formulações terapêuticas
BRPI0509389A (pt) associação entre um composto heterocìclico e um agente antioxidante e sua utilização para o tratamento da obesidade

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.